Form 8-K

8-K — IMMUNIC, INC.

Accession: 0001193805-26-000593

Filed: 2026-05-13

Period: 2026-05-13

CIK: 0001280776

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — e665461_8k-immunic.htm (Primary)

EX-99.1 (e665461_ex99-1.htm)

GRAPHIC (image_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: e665461_8k-immunic.htm · Sequence: 1

false

0001280776

2026-05-13

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May

13, 2026

IMMUNIC, INC.

(Exact name of registrant as specified in its

charter)

Delaware

001-36201

56-2358443

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

1200 Avenue of the Americas, Suite 200

New York, NY 10036

USA

(Address of principal executive offices)

Registrant’s telephone number, including

area code: (332) 255-9818

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of exchange on which registered

Common Stock, par value $0.0001

IMUX

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange

Act of 1934 (§ 240.12b2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. Yes ☐ No ☐

Item 2.02. Results of Operations and Financial Condition

On May 13 2026, Immunic, Inc. (the “Company”)

issued a press release, a copy of which is furnished herewith as Exhibit 99.1, announcing the Company’s financial results for the

quarter ended March 31, 2026, and providing a corporate update (the “Press Release”).

The information contained in Item 2.02 of this

Current Report on Form 8-K, including the Press Release, shall not be deemed “filed” for the purposes of Section 18 of the

Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section or Sections 11 and 12(a)(2) of the

Securities Act of 1933, as amended. In addition, this information shall not be deemed incorporated by reference into any of the Company’s

filings with the Securities and Exchange Commission, except as shall be expressly set forth by specific reference in any such filing.

Item 9.01. Financial Statements and Exhibits

Exhibit

Description

99.1

Press Release, dated May 13, 2026.

104

Cover Page to this Current Report on Form 8-K in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934,

as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Dated: May 13, 2026

Immunic, Inc.

By:

/s/ Daniel Vitt

Daniel Vitt

Chief Executive Officer

EX-99.1

Filename: e665461_ex99-1.htm · Sequence: 2

Immunic, Inc. Reports First

Quarter 2026 Financial Results and Provides Corporate Update

–

Appointed Globally Renowned Biopharmaceutical Executive and Neurology Drug Developer, Michael A. Panzara, M.D., M.P.H., as Chief Medical

Officer –

–

Continued to Execute Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis, with Top-Line Data Expected

by End of 2026 –

–

Raised $200 Million in an Oversubscribed Private Placement, with Potential for up to an Additional $200 Million –

NEW YORK,

May 13, 2026 – Immunic, Inc. (Nasdaq:

IMUX), a late-stage biotechnology company pioneering the development of novel oral

therapies for neurologic diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a

corporate update.

“We are fast approaching a highly pivotal

juncture, with the anticipated top-line data readout of the twin phase 3 ENSURE trials of our lead asset, orally available nuclear receptor-related

1 (Nurr1) activator, vidofludimus calcium (IMU-838), in relapsing multiple sclerosis (RMS), expected by the end of 2026,” stated

Daniel Vitt, Ph.D., Chief Executive Officer of Immunic. “In anticipation, we strengthened our leadership team with the recent appointment

of Dr. Michael A. Panzara as Chief Medical Officer. Mike brings deep expertise in neurology and a proven track record of advancing multiple

sclerosis (MS) therapies through late-stage clinical development and global regulatory approvals. Additionally, we enhanced our Board

of Directors with the appointment of Jon Congleton, who has nearly four decades of biopharmaceutical leadership experience. Earlier in

the quarter, Simona Skerjanec, M.Pharm, M.B.A., who joined Immunic's Board of Directors in July 2024, has been elevated to interim Chairperson

of the Board and Thor Nagel, Principal at BVF Partners L.P., has been appointed as a member of the Board. Together, these key appointments

are intended to best position the company for successful execution of our late-stage development priorities and prepare for potential

commercialization.”

Dr. Vitt continued, “As important, in February,

we closed an oversubscribed private placement financing of up to $400 million in gross proceeds, with $200 million received upfront. This

highly successful transaction signals investors’ continued confidence in Immunic and has provided the resources we need to advance

our programs through key milestones and to continue our transition into a commercial-stage company. The initial proceeds are expected

to fund our operations through the completion of our phase 3 ENSURE trials in RMS and our planned RMS New Drug Application (NDA) submission

in the United States in mid-2027. The funds will also support continued investment in our development organization and launch readiness.

At the same time, we remain focused on expanding the opportunity for vidofludimus calcium beyond RMS, which is supported by the growing

body of data from our phase 2 CALLIPER trial in progressive MS (PMS) and our plan to initiate a confirmatory phase 3 program in primary

progressive MS (PPMS) later this year.”

Jason Tardio, President and Chief Operating Officer

of Immunic, added, “We believe vidofludimus calcium has the potential to offer a transformative approach to disease modification

in MS. Unlike currently available oral therapies that primarily target inflammatory pathways, vidofludimus calcium is designed to deliver

both direct neuroprotective effects through Nurr1 activation and anti-inflammatory activity via selective DHODH inhibition. In clinical

trials to date, vidofludimus calcium has demonstrated a favorable safety and tolerability profile. Taken together, these attributes may

support a compelling benefit-risk profile in the global MS market, which is projected to exceed $30 billion by the early 2030s.”

First Quarter 2026 and Subsequent Highlights

· April 2026: Appointed accomplished biopharmaceutical executive Michael

A. Panzara, M.D., M.P.H., as Chief Medical Officer, to lead the company’s development organization, including clinical development,

medical affairs, and regulatory affairs. Dr. Panzara succeeds Andreas Muehler, M.D., M.B.A., who will continue to support the company

as a consultant.

· April 2026: Effected 1-for-10 reverse stock split of the outstanding

shares of common stock as of April 27, 2026.

· April 2026: Regained compliance with Nasdaq minimum bid price requirement

(Rule 5550(a)(2)) for continued listing, following receipt of a written notice on March 27, 2026.

· March 2026: Appointed Jon Congleton, a seasoned biopharmaceutical

executive with nearly 40 years of experience spanning drug development, commercialization and corporate leadership, to the Board of Directors.

· March 2026: Announced grant of a key European patent from the European

Patent Office (EPO) directed to label-relevant dosing regimens of vidofludimus calcium. The patent is expected to provide protection

into 2038 and may be eligible for a Supplementary Protection Certificate (SPC), which could extend market exclusivity potentially into

2043. This patent was previously granted by the United States Patent and Trademark Office (USPTO) in 2023.

· February 2026: Completed an oversubscribed private placement financing

of up to $400 million in gross proceeds, led by existing investor BVF Partners L.P. with participation from Aberdeen Investments, Avidity

Partners, Coastlands Capital, EcoR1 Capital, Janus Henderson Investors, OrbiMed, RA Capital Management, TCGX, Trails Edge Capital Partners,

Vivo Capital, Woodline Partners LP, and other institutional investors. A total of $200 million in gross proceeds to Immunic was received

upon closing on February 17, 2026.

o Elevated Simona Skerjanec, former SVP, Global Head of Neuroscience

and Rare Diseases at Roche, to Interim Chairperson of the Board of Directors. Dr. Duane Nash, former Chairman, remains a member of the

Board. Appointed Thor Nagel, Principal at BVF Partners L.P., to the Board. Plans underway for further Board refreshment to support the

company’s evolution into a commercial-stage organization.

o Initiated search for a new Chief Executive Officer with deep commercial

expertise in neurology to lead Immunic into its next stage of growth and commercialization. Subsequently, Dr. Vitt will return

to his roots and transition to a new senior executive role focused on scientific strategy and portfolio

advancement, while remaining on the Board.

· February 2026: Presented additional data from the phase 2 CALLIPER

trial of vidofludimus calcium in patients with PMS at the ACTRIMS Forum 2026 in San Diego, California. The findings, presented in two

poster presentations, provide additional evidence of vidofludimus calcium’s effects on key biological drivers of disease progression,

including antiviral immune responses linked to Epstein-Barr virus (EBV) and magnetic resonance imaging (MRI) markers of both acute-focal

and chronic-compartmentalized inflammation. The findings further reinforce Immunic’s belief that vidofludimus calcium has the potential

to address underlying mechanisms of disease progression in MS patients.

Anticipated Clinical Milestones

· Vidofludimus calcium in MS:

o Top-line data from the twin phase 3 ENSURE-1 and ENSURE-2 trials in RMS is expected by the end of 2026.

Subsequently, Immunic plans to submit an NDA in the United States in mid-2027, with a targeted potential regulatory approval date in 2028.

o Initiation of a phase 3 clinical program in PPMS is expected later this year and is estimated to take

approximately 3.5 to 4 years to complete.

· IMU-856: The company is currently exploring strategic alternatives for the IMU-856 program and

is open to discussing potential financing, licensing or partnering options with interested parties.

Financial and Operating Results

· Research and Development (R&D) Expenses were $25.6 million for the three months ended March

31, 2026, as compared to $21.5 million for the three months ended March 31, 2025. The $4.1 million increase reflects (i) a $2.9 million

increase in external development costs related to the vidofludimus calcium program, (ii) a $1.0 million increase in personnel expenses,

$0.7 million of which was related to non-cash stock compensation and (iii) a $0.2 million increase related to costs across numerous categories.

· General and Administrative (G&A) Expenses were $7.6 million for the three months ended March

31, 2026, as compared to $5.3 million for the same period ended March 31, 2025. The $2.3 million increase was due to (i) a $2.0 million

increase related to personnel expenses, of which $1.8 million was related to non-cash stock compensation, (ii) a $0.2 million increase

in legal and consultancy expenses, (iii) a $0.2 million increase in marketing expenses, which was partially offset by a $0.1 million decrease

related to costs across numerous categories.

· Interest Income was $0.8 million for the three months ended March 31, 2026, as compared to $0.2

million for the three months ended March 31, 2025. The $0.6 million increase was due to a higher average cash balance as a result of the

February 2026 Private Placement.

· Other Income (Expense) was ($0.1) million for the three months ended March 31, 2026, as compared

to $1.2 million for the same period ended March 31, 2025. The $1.3 million decrease was primarily attributable to (i) a $1.1 million grant

income of the German Federal Ministry of Finance recognized in the first quarter 2025 and no grant income in 2026 and (ii) a $0.2 million

decrease across numerous categories.

· Net Loss for the three months ended March 31, 2026, was approximately $32.6 million, or $1.08 per

basic and diluted share, based on 30,136,324 weighted average common shares outstanding, compared to a net loss of approximately $25.5

million, or $2.51 per basic and diluted share, based on 10,134,443 weighted average common shares outstanding for the same period ended

March 31, 2025.

· Cash and Cash Equivalents as of March 31, 2026 were $186.6 million. With these funds, Immunic expects

to be able to fund its operations into late 2027.

About Immunic,

Inc.

Immunic, Inc. (Nasdaq:

IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company’s

lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for the treatment of relapsing multiple

sclerosis, for which top-line data is expected to be available by the end of 2026. It has already shown therapeutic activity in phase

2 clinical trials in relapsing-remitting multiple sclerosis, progressive multiple sclerosis and other diseases. Vidofludimus calcium combines

neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory

and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). The company’s development pipeline

also includes earlier-stage programs, including IMU-856 and IMU-381, aimed at building a broader therapeutics platform addressing neurodegenerative,

chronic inflammatory, and autoimmune-related diseases. For further information, please visit: www.imux.com.

Cautionary

Statement Regarding Forward-Looking Statements

This press release contains "forward-looking

statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation

Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future

operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development

and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements

include, but are not limited to, statements relating to Immunic's development programs and the targeted diseases; the potential for Immunic's

development programs to safely and effectively target diseases; preclinical and clinical data for Immunic's development programs; the

feasibility of advancing vidofludimus calcium to a confirmatory phase 3 clinical trial in progressive multiple sclerosis; the timing of

current and future clinical trials, anticipated clinical milestones and regulatory approvals; the nature, strategy and focus of the company

and further updates with respect thereto; the development and commercial potential of any product candidates of the company; expectations

regarding the capitalization, resources and ownership structure of the company; and the executive and board structure of the company.

Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking

statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s

current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those

projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs

and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical

trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future

liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational

requirements, and the ability to raise sufficient capital to continue as a going concern, the fact that the results of earlier preclinical

studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for

the company’s products or product candidates, the protection and market exclusivity provided by Immunic’s intellectual property,

risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes.

A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned “Risk Factors,”

in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 26, 2026,

and in the company’s subsequent filings with the SEC. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings.

Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation

to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic

expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.

Contact Information

Immunic, Inc.

Jessica Breu

Vice President Investor Relations and Communications

+49 89 2080 477 09

jessica.breu@imux.com

US IR Contact

Rx Communications Group

Paula Schwartz

+1 917 633 7790

immunic@rxir.com

US Media Contact

KCSA Strategic Communications

Caitlin Kasunich

+1 212 896 1241

ckasunich@kcsa.com

Financials

Immunic, Inc.

Condensed Consolidated Statements of Operations

(In thousands, except share and per share amounts)

(Unaudited)

Three Months

Ended March 31,

2026

2025

Operating expenses:

Research and development

$ 25,626

$ 21,533

General and administrative

7,609

5,292

Total operating expenses

33,235

26,825

Loss from operations

(33,235 )

(26,825 )

Other income:

Interest income

760

183

Other income (expense), net

(113 )

1,169

Total other income

647

1,352

Net loss

$ (32,588 )

$ (25,473 )

Net loss per share, basic and diluted

$ (1.08 )

$ (2.51 )

Weighted-average common shares outstanding, basic and diluted

30,136,324

10,134,443

Immunic, Inc.

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

(Unaudited)

March 31, 2026

December 31, 2025

(Unaudited)

Assets

Current assets:

Cash and cash equivalents

$ 186,629

$ 15,483

Prepaid expenses and other current assets

2,130

7,386

Total current assets

188,759

22,869

Property and equipment, net

566

608

Right-of-use assets, net

417

575

Total assets

$ 189,742

$ 24,052

Liabilities and Stockholders’ Equity (Deficit)

Current liabilities:

Accounts payable

$ 11,011

$ 10,138

Accrued expenses

22,432

18,645

Other current liabilities

4,920

1,835

Total current liabilities

38,363

30,618

Long-term liabilities

Operating lease liabilities

146

107

Total long-term liabilities

146

107

Total liabilities

38,509

30,725

Commitments and contingencies

Stockholders’ equity (deficit):

Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding as of March 31, 2026 and December 31, 2025

—

Common stock, $0.0001 par value; 500,000,000 shares authorized as of March 31, 2026 and December 31, 2025 and 13,621,483 and 12,038,263 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively.

Additional paid-in capital

789,324

599,241

Accumulated other comprehensive income

3,057

2,648

Accumulated deficit

(641,159 )

(608,571 )

Total stockholders’ equity (deficit)

151,233

(6,673 )

Total liabilities and stockholders’ equity (deficit)

$ 189,742

$ 24,052

GRAPHIC

Filename: image_001.jpg · Sequence: 6

Binary file (3195 bytes)

Download image_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

May 13, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 13, 2026

Entity File Number

001-36201

Entity Registrant Name

IMMUNIC, INC.

Entity Central Index Key

0001280776

Entity Tax Identification Number

56-2358443

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1200 Avenue of the Americas

Entity Address, Address Line Two

Suite 200

Entity Address, City or Town

New York

Entity Address, State or Province

Entity Address, Country

Entity Address, Postal Zip Code

10036

City Area Code

(332)

Local Phone Number

255-9818

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.0001

Trading Symbol

IMUX

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

ISO 3166-1 alpha-2 country code.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCountry

Namespace Prefix:

dei_

Data Type:

dei:countryCodeItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration